View of Pharmacoeconomic Evaluation and Clinical Outcomes of Channa as an Adjuvant to 20% Human Albumin Therapy in Patients with Chronic Kidney Disease: A Cost-Effectiveness Analysis (CEA) at Imelda Pekerja Indonesia General Hospital

Return to Article Details Pharmacoeconomic Evaluation and Clinical Outcomes of Channa as an Adjuvant to 20% Human Albumin Therapy in Patients with Chronic Kidney Disease: A Cost-Effectiveness Analysis (CEA) at Imelda Pekerja Indonesia General Hospital Download Download PDF